Mosaic Therapeutics

The mean 5-year survival across all cancer types is 51 per cent, and cancer drug development has a 93 per cent clinical failure rate. Mosaic’s proprietary drug discovery platform addresses these issues by combining advanced computation, large dataset mining and experimental biology to identify and develop novel targeted therapies that are safer and more effective.

In 2023, the company closed a $28 million series A funding round from Syncona Investment Management, Ltd, and Cambridge Innovation Capital.

Mosaic’s proprietary platform applies research from co-founder Dr Mathew Garnett’s Translational Cancer Genomics Laboratory at the Wellcome Sanger Institute. Dr Garnett is a senior group leader at Sanger with over 20 years’ experience in genomics and cancer therapeutics, with past achievements including co-discovery of BRAF mutations in cancer and Werner Syndrome helicase as a target in MSI tumours.